JP2023516774A5 - - Google Patents
Info
- Publication number
- JP2023516774A5 JP2023516774A5 JP2022553666A JP2022553666A JP2023516774A5 JP 2023516774 A5 JP2023516774 A5 JP 2023516774A5 JP 2022553666 A JP2022553666 A JP 2022553666A JP 2022553666 A JP2022553666 A JP 2022553666A JP 2023516774 A5 JP2023516774 A5 JP 2023516774A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- pharmaceutical composition
- composition according
- administration
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305241.0 | 2020-03-06 | ||
| EP20305241 | 2020-03-06 | ||
| PCT/EP2021/055570 WO2021176044A1 (en) | 2020-03-06 | 2021-03-05 | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516774A JP2023516774A (ja) | 2023-04-20 |
| JP2023516774A5 true JP2023516774A5 (https=) | 2024-02-22 |
| JP7840267B2 JP7840267B2 (ja) | 2026-04-03 |
Family
ID=71083549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553666A Active JP7840267B2 (ja) | 2020-03-06 | 2021-03-05 | 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230090069A1 (https=) |
| EP (2) | EP4647123A3 (https=) |
| JP (1) | JP7840267B2 (https=) |
| AU (1) | AU2021230103A1 (https=) |
| CA (1) | CA3166887A1 (https=) |
| ES (1) | ES3041723T3 (https=) |
| TW (1) | TWI894224B (https=) |
| WO (1) | WO2021176044A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4630035A1 (en) | 2022-12-05 | 2025-10-15 | Centre Hospitalier Universitaire de Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
| AU2024238511A1 (en) * | 2023-03-21 | 2025-10-02 | Coya Therapeutics, Inc. | Biomarkers of amyotrophic lateral sclerosis and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341562C (en) | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
| IE56026B1 (en) | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| IL76591A0 (en) * | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| RU2322452C2 (ru) * | 2006-03-27 | 2008-04-20 | Михаил Николаевич Смирнов | Иммуномодулирующая композиция |
| DK2683395T3 (en) | 2011-03-11 | 2018-11-19 | Hopitaux Paris Assist Publique | USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| JP7422480B2 (ja) | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
-
2021
- 2021-03-05 JP JP2022553666A patent/JP7840267B2/ja active Active
- 2021-03-05 EP EP25184617.6A patent/EP4647123A3/en active Pending
- 2021-03-05 US US17/904,734 patent/US20230090069A1/en active Pending
- 2021-03-05 CA CA3166887A patent/CA3166887A1/en active Pending
- 2021-03-05 AU AU2021230103A patent/AU2021230103A1/en active Pending
- 2021-03-05 TW TW110107972A patent/TWI894224B/zh active
- 2021-03-05 EP EP21709019.0A patent/EP4114440B1/en active Active
- 2021-03-05 ES ES21709019T patent/ES3041723T3/es active Active
- 2021-03-05 WO PCT/EP2021/055570 patent/WO2021176044A1/en not_active Ceased
-
2024
- 2024-06-18 US US18/746,819 patent/US20240335510A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schulze et al. | Effect of combined prednisolone, epidural analgesia, and indomethacin on the systemic response after colonic surgery | |
| EP2056838B1 (en) | Combination therapy for treatment of immune disorders | |
| RU2676333C2 (ru) | Способы снижения частоты приступов астмы с применением бенрализумаба | |
| JP2014523882A5 (https=) | ||
| RU2703568C2 (ru) | Способы повышения форсированного объема выдоха у больных астмой с применением бенрализумаба | |
| JP2023516774A5 (https=) | ||
| EP2844291B1 (en) | Methods for treating idiopathic pulmonary fibrosis | |
| ES2901634T3 (es) | Métodos para mejorar los síntomas de asma mediante el uso de benralizumab | |
| US20120214729A1 (en) | Composition for preventing or treating inflammation | |
| US20240335510A1 (en) | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis | |
| Bahari et al. | Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection | |
| Schmidt et al. | Lethal capillary leak syndrome after a single administration of interferon beta-1b | |
| Esposito et al. | Natural killer cells in Bal and peripheral blood of patients with idiopathic pulmonary fibrosis (IPF) | |
| Safari et al. | A comparative study of influence of isoflurane and propofol on IL1, IL6, TNF serum levels after craniotomy for supratentorial brain tumors | |
| US20210393628A1 (en) | Compositions and methods for modulating t cell exhaustion | |
| Kamit et al. | A fatal case of COVID-19 in a child with ALL: A cytokine storm and hyperferritinemic MODS | |
| Fireman et al. | Suppressor cell activity of human alveolar macrophages in interstitial lung diseases | |
| Kronfol et al. | Plasma cytokines, acute phase proteins and cortisol in major depression | |
| US20230181491A1 (en) | Compositions and methods for the treatment and management of inflammation using hydroxynorketamine | |
| Paller et al. | 112: Laboratory parameters in adolescent patients aged 12-17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to Week 52: results from the phase 3 ECZTRA 6 trial | |
| Jabłońska et al. | Anakinra—a modern immunomodulatory drug with broad applicability in severe systemic inflammatory reactions—part 1. History, mechanism of action, pharmacokinetics, side effects, interactions, dosage | |
| Paller et al. | 110: Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: Study design of phase 3 OCEANA clinical trials COAST1/2, SHORE, AQUA, and ESTUARY | |
| Paller et al. | 111: High Proportions of Adolescents Achieved Topical-Free Periods over 1 Year While Taking Lebrikizumab for Treatment of Moderate-to-Severe Atopic Dermatitis | |
| Peinado et al. | Japan Journal of Research | |
| KR20220008041A (ko) | 조혈 줄기세포의 가동을 위한 물질-p의 배합 요법 |